New hope for breast cancer patients: drug may prevent dangerous drop in blood cells
NCT ID NCT07243418
First seen Nov 21, 2025 · Last updated Apr 26, 2026 · Updated 23 times
Summary
This study tests whether the drug hetrombopag can prevent or reduce low platelet counts caused by a type of breast cancer treatment called ADC drugs. It involves 72 breast cancer patients who are about to start or have already had low platelets from these drugs. The goal is to see if hetrombopag can help manage this side effect and keep treatment on track.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.